Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.41 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8563242 | 0.84 | IGF1R (0.54) | ALDH1A1POLBTDP1MEN1KMT2A | |
| SCHEMBL28044640 | 0.80 | ALDH1A1 (0.66) | ALDH1A1POLBTDP1NCOA1NCOA3 | |
| SCHEMBL28252545 | 0.77 | ALDH1A1 (0.66) | ALDH1A1POLBTDP1NCOA1NCOA3 | |
| SCHEMBL1200287 | 0.77 | ALDH1A1 (0.66) | ALDH1A1POLBTDP1NCOA1NCOA3 | |
| SCHEMBL28286502 | 0.77 | ALDH1A1 (0.66) | ALDH1A1POLBTDP1NCOA1NCOA3 | |
| SCHEMBL6272457 | 0.77 | ALDH1A1 (0.66) | ALDH1A1POLBTDP1NCOA1NCOA3 | |
| SCHEMBL3955324 | 0.77 | ALDH1A1 (1.00) | ALDH1A1POLBTDP1NCOA1NCOA3 | |
| SCHEMBL4818048 | 0.77 | ALDH1A1 (0.66) | ALDH1A1POLBTDP1NCOA1NCOA3 | |
| SCHEMBL27795495 | 0.75 | ALDH1A1 (0.64) | ALDH1A1POLBTDP1NCOA1NCOA3 | |
| SCHEMBL8331153 | 0.75 | ALDH1A1 (0.63) | ALDH1A1POLBTDP1NCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1659144-B | Quinoline and isoquinoline derivatives, process for their preparation and their use as inflammation inhibitors | SCHERING AG | 2010-09-08 | — | — | CN | disclosed |
| US-7329753-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2008-02-12 | — | — | US | disclosed |
| EP-1492771-B1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
| US-7109212-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2006-09-19 | — | — | US | disclosed |
| CN-1659144-A | Quinoline and isoquinoline derivatives, process for their preparation and their use as inflammation inhibitors | SCHERING AG (DE) | 2005-08-24 | — | — | CN | disclosed |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-28 | — | — | US | disclosed |
| US-6897224-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2005-05-24 | — | — | US | disclosed |
| EP-1492771-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040116694-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2004-06-17 | — | — | US | disclosed |
| WO-2003082827-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | ALDH1A1 1538/4885POLB 1624/4885TDP1 3228/4885 |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | ALDH1A1 1538/4885POLB 1624/4885TDP1 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.